 placebo-controlled trial maintenance therapy fluconazole treatment cryptococcal meningitis acquired immunodeficiency syndrome California Collaborative Treatment Group BACKGROUND AND METHODS patients acquired immunodeficiency syndrome AIDS rate relapse primary treatment cryptococcal meningitis high double-blind trial efficacy maintenance therapy fluconazole entry study participants sterile cultures cerebrospinal fluid blood urine standardized course therapy culture-proved cryptococcal meningitis patients fluconazole placebo maintenance therapy dose fluconazole mg first phase study mg second phase RESULTS patients percent silent persistent infection basis cultures positive entry study patients follow-up entry patients percent percent recurrence cryptococcal infection site difference risk percent percent confidence interval recurrent infections urine prostatic massage recurrent meningeal infections patients placebo none fluconazole mean duration follow-up days multivariate analyses predictors recurrence-free survival fluconazole treatment relative hazard serum cryptococcal-antigen titer relative hazard prolonged primary therapy flucytosine relative hazard Survival toxicity similar maintenance-treatment groups CONCLUSIONS patients AIDS silent persistent infection common successful treatment cryptococcal meningitis Maintenance therapy fluconazole effective recurrent cryptococcal infection